Risperidone in the treatment of psychosis of Alzheimer disease: Results from a prospective clinical trial

Jacobo Mintzer, Andrew Greenspan, Ivo Caers, Ilse Van Hove, Stuart Kushner, Myron Weiner, Georges Gharabawi, Lon S. Schneider

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Objective: The objective of this study was to evaluate efficacy and safety of low-dose risperidone for treating psychosis of Alzheimer disease (AD). Method: The authors conducted a randomized, eight-week, double-blind, placebo-controlled, multicenter trial involving nursing home residents diagnosed with AD and psychosis. Four hundred seventy-three patients were randomly assigned to placebo (N = 238) or 1.0 to 1.5 mg risperidone per day (N = 235). Coprimary efficacy end points were: changes in scores on the Behavioral pathology in Alzheimer's Disease (BEHAVE-AD) Psychosis subscale and Clinical Global Impression of Change (CGI-C). Protocol-specified subgroup analyses were performed by demographics and dementia severity. Results: Efficacy analysis included 416 patients. Both groups improved significantly on the BEHAVE-AD Psychosis subscale and CGI-C with no significant difference between groups. In the subgroups analyses, a statistically significant treatment by Mini-Mental Status Examination (MMSE) interaction on the CGI-C (F[2,381] = 3.90, p = 0.021) was observed with patients with more severe dementia (MMSE <10) showing significant differences at end point favoring risperidone treatment (χ2 [1] = 5.11, p = 0.024). Mean risperidone dose was 1.03 ± 0.24 mg per day. All-cause discontinuation rates were 25% for both risperidone and placebo. Treatment-emergent adverse events occurred in 74% risperidone versus 64% placebo patients, with somnolence occurring significantly more frequently with risperidone (16.2% versus 4.6%). Nine (3.8%) risperidone- and six (2.5%) placebo patients died during or within 30 days after treatment. Conclusion: This trial did not confirm earlier findings in this population.

Original languageEnglish (US)
Pages (from-to)280-291
Number of pages12
JournalAmerican Journal of Geriatric Psychiatry
Volume14
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Risperidone
Psychotic Disorders
Alzheimer Disease
Clinical Trials
Placebos
Therapeutics
Dementia
Nursing Homes
Multicenter Studies
Demography
Pathology
Safety

Keywords

  • Alzheimer disease
  • Psychosis
  • Risperidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology

Cite this

Risperidone in the treatment of psychosis of Alzheimer disease : Results from a prospective clinical trial. / Mintzer, Jacobo; Greenspan, Andrew; Caers, Ivo; Van Hove, Ilse; Kushner, Stuart; Weiner, Myron; Gharabawi, Georges; Schneider, Lon S.

In: American Journal of Geriatric Psychiatry, Vol. 14, No. 3, 03.2006, p. 280-291.

Research output: Contribution to journalArticle

Mintzer, J, Greenspan, A, Caers, I, Van Hove, I, Kushner, S, Weiner, M, Gharabawi, G & Schneider, LS 2006, 'Risperidone in the treatment of psychosis of Alzheimer disease: Results from a prospective clinical trial', American Journal of Geriatric Psychiatry, vol. 14, no. 3, pp. 280-291. https://doi.org/10.1097/01.JGP.0000194643.63245.8c
Mintzer, Jacobo ; Greenspan, Andrew ; Caers, Ivo ; Van Hove, Ilse ; Kushner, Stuart ; Weiner, Myron ; Gharabawi, Georges ; Schneider, Lon S. / Risperidone in the treatment of psychosis of Alzheimer disease : Results from a prospective clinical trial. In: American Journal of Geriatric Psychiatry. 2006 ; Vol. 14, No. 3. pp. 280-291.
@article{c58b469125dd426ead31ed07492be269,
title = "Risperidone in the treatment of psychosis of Alzheimer disease: Results from a prospective clinical trial",
abstract = "Objective: The objective of this study was to evaluate efficacy and safety of low-dose risperidone for treating psychosis of Alzheimer disease (AD). Method: The authors conducted a randomized, eight-week, double-blind, placebo-controlled, multicenter trial involving nursing home residents diagnosed with AD and psychosis. Four hundred seventy-three patients were randomly assigned to placebo (N = 238) or 1.0 to 1.5 mg risperidone per day (N = 235). Coprimary efficacy end points were: changes in scores on the Behavioral pathology in Alzheimer's Disease (BEHAVE-AD) Psychosis subscale and Clinical Global Impression of Change (CGI-C). Protocol-specified subgroup analyses were performed by demographics and dementia severity. Results: Efficacy analysis included 416 patients. Both groups improved significantly on the BEHAVE-AD Psychosis subscale and CGI-C with no significant difference between groups. In the subgroups analyses, a statistically significant treatment by Mini-Mental Status Examination (MMSE) interaction on the CGI-C (F[2,381] = 3.90, p = 0.021) was observed with patients with more severe dementia (MMSE <10) showing significant differences at end point favoring risperidone treatment (χ2 [1] = 5.11, p = 0.024). Mean risperidone dose was 1.03 ± 0.24 mg per day. All-cause discontinuation rates were 25{\%} for both risperidone and placebo. Treatment-emergent adverse events occurred in 74{\%} risperidone versus 64{\%} placebo patients, with somnolence occurring significantly more frequently with risperidone (16.2{\%} versus 4.6{\%}). Nine (3.8{\%}) risperidone- and six (2.5{\%}) placebo patients died during or within 30 days after treatment. Conclusion: This trial did not confirm earlier findings in this population.",
keywords = "Alzheimer disease, Psychosis, Risperidone",
author = "Jacobo Mintzer and Andrew Greenspan and Ivo Caers and {Van Hove}, Ilse and Stuart Kushner and Myron Weiner and Georges Gharabawi and Schneider, {Lon S.}",
year = "2006",
month = "3",
doi = "10.1097/01.JGP.0000194643.63245.8c",
language = "English (US)",
volume = "14",
pages = "280--291",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Risperidone in the treatment of psychosis of Alzheimer disease

T2 - Results from a prospective clinical trial

AU - Mintzer, Jacobo

AU - Greenspan, Andrew

AU - Caers, Ivo

AU - Van Hove, Ilse

AU - Kushner, Stuart

AU - Weiner, Myron

AU - Gharabawi, Georges

AU - Schneider, Lon S.

PY - 2006/3

Y1 - 2006/3

N2 - Objective: The objective of this study was to evaluate efficacy and safety of low-dose risperidone for treating psychosis of Alzheimer disease (AD). Method: The authors conducted a randomized, eight-week, double-blind, placebo-controlled, multicenter trial involving nursing home residents diagnosed with AD and psychosis. Four hundred seventy-three patients were randomly assigned to placebo (N = 238) or 1.0 to 1.5 mg risperidone per day (N = 235). Coprimary efficacy end points were: changes in scores on the Behavioral pathology in Alzheimer's Disease (BEHAVE-AD) Psychosis subscale and Clinical Global Impression of Change (CGI-C). Protocol-specified subgroup analyses were performed by demographics and dementia severity. Results: Efficacy analysis included 416 patients. Both groups improved significantly on the BEHAVE-AD Psychosis subscale and CGI-C with no significant difference between groups. In the subgroups analyses, a statistically significant treatment by Mini-Mental Status Examination (MMSE) interaction on the CGI-C (F[2,381] = 3.90, p = 0.021) was observed with patients with more severe dementia (MMSE <10) showing significant differences at end point favoring risperidone treatment (χ2 [1] = 5.11, p = 0.024). Mean risperidone dose was 1.03 ± 0.24 mg per day. All-cause discontinuation rates were 25% for both risperidone and placebo. Treatment-emergent adverse events occurred in 74% risperidone versus 64% placebo patients, with somnolence occurring significantly more frequently with risperidone (16.2% versus 4.6%). Nine (3.8%) risperidone- and six (2.5%) placebo patients died during or within 30 days after treatment. Conclusion: This trial did not confirm earlier findings in this population.

AB - Objective: The objective of this study was to evaluate efficacy and safety of low-dose risperidone for treating psychosis of Alzheimer disease (AD). Method: The authors conducted a randomized, eight-week, double-blind, placebo-controlled, multicenter trial involving nursing home residents diagnosed with AD and psychosis. Four hundred seventy-three patients were randomly assigned to placebo (N = 238) or 1.0 to 1.5 mg risperidone per day (N = 235). Coprimary efficacy end points were: changes in scores on the Behavioral pathology in Alzheimer's Disease (BEHAVE-AD) Psychosis subscale and Clinical Global Impression of Change (CGI-C). Protocol-specified subgroup analyses were performed by demographics and dementia severity. Results: Efficacy analysis included 416 patients. Both groups improved significantly on the BEHAVE-AD Psychosis subscale and CGI-C with no significant difference between groups. In the subgroups analyses, a statistically significant treatment by Mini-Mental Status Examination (MMSE) interaction on the CGI-C (F[2,381] = 3.90, p = 0.021) was observed with patients with more severe dementia (MMSE <10) showing significant differences at end point favoring risperidone treatment (χ2 [1] = 5.11, p = 0.024). Mean risperidone dose was 1.03 ± 0.24 mg per day. All-cause discontinuation rates were 25% for both risperidone and placebo. Treatment-emergent adverse events occurred in 74% risperidone versus 64% placebo patients, with somnolence occurring significantly more frequently with risperidone (16.2% versus 4.6%). Nine (3.8%) risperidone- and six (2.5%) placebo patients died during or within 30 days after treatment. Conclusion: This trial did not confirm earlier findings in this population.

KW - Alzheimer disease

KW - Psychosis

KW - Risperidone

UR - http://www.scopus.com/inward/record.url?scp=33644885707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644885707&partnerID=8YFLogxK

U2 - 10.1097/01.JGP.0000194643.63245.8c

DO - 10.1097/01.JGP.0000194643.63245.8c

M3 - Article

C2 - 16505133

AN - SCOPUS:33644885707

VL - 14

SP - 280

EP - 291

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 3

ER -